Research programme: recombinant human fibrinogen - Pharming

Drug Profile

Research programme: recombinant human fibrinogen - Pharming

Alternative Names: rhFIB

Latest Information Update: 31 Dec 2008

Price : $50

At a glance

  • Originator Pharming Group NV
  • Class Acute-phase proteins; Blood coagulation factors; Protein precursors; Recombinant proteins
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Afibrinogenaemia

Most Recent Events

  • 31 Dec 2008 Early research is ongoing in the Netherlands
  • 16 Oct 2007 The recombinant human fibrinogen product receives orphan drug status for the treatment of bleeding in patients deficient in fibrinogen in the US
  • 16 Oct 2007 Early research in Afibrinogenaemia in the Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top